Phase Bioscience has closed on new financing along with a major partner.

Johnson & Johnson Development Corp. has invested an undisclosed amount of money in Phase Bioscience. As part of the deal, Carol Marino, vice president of venture investments for Johnson & Johnson, will join the Phase Bioscience board of directors.

Hatteras Venture Partners is also an investor in Phase Bioscience.

Phase Bioscience announced in December that it had licensed drug-discovery technology from Duke University. The new funding will be used to advance that technology, Phase Bioscience said.

The Duke technology is designed to enhance drug delivery and improve efficacy. Phase Bioscience also has its own drug purification and delivery process.

“This is a significant equity investment for Phase Bioscience and will allow the company to move forward with the development of the purification and the new drug delivery technologies recently acquired from Duke University,” said Gabriel Cipau, chairman and CEO of Phase Bioscience.

“The company’s technology has the potential to deliver pharmaceutical products with greater efficacy and lower side effects and make an impact on the ability to cost-ffectively purify therapeutic proteins and peptides,” he added.

Johnson & Johnson Development Corp. is the venture capital arm of Johnson & Johnson.

In addition to drug development, Phase Bioscience also offers manufacturing services and processes.

Phase Bioscience recently received a $50,000 state grant for a program using biosynthetic methods to enable the development of new medicines more rapidly and at significantly lower cost. The project is sponsored by the National Institutes of Health.